SCHEMBL4286138

SCHEMBL4286138

CC(C)(C)c1ccc(CN2CCC(N(C3CC3)S(=O)(=O)c3ccccc3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
CACNA1B Q00975 1/20 0.50
HTR2A P28223 4/20 0.48
KCNH2 Q12809 4/20 0.47
HTR2C P28335 2/20 0.47
DRD2 P14416 3/20 0.47
HTR2B P41595 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
CXCR4 P61073 2/20 0.46
GPR119 Q8TDV5 2/20 0.44
HTR1A P08908 1/20 0.44
HTR7 P34969 1/20 0.44
LMNA P02545 1/20 0.43
NR1I2 O75469 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CNR1 P21554 1/20 0.43
HRH1 P35367 1/20 0.43
OPRK1 P41145 1/20 0.43
PDE4D Q08499 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14997384 0.88 HTR2A (0.61) CACNA1BHTR2ADRD2SIGMAR1CXCR4
SCHEMBL4285276 0.85 CHRM4 (0.56) CACNA1BHTR2AKCNH2HTR2CCXCR4
SCHEMBL4282387 0.85 ALDH1A1 (0.51) CACNA1BHTR2AKCNH2HTR2CDRD2
SCHEMBL4285152 0.84 SIGMAR1 (0.56) MEN1KMT2ACACNA1BHTR2ASIGMAR1
SCHEMBL4284277 0.84 HTR2A (0.48) CACNA1BHTR2AHTR2CDRD2CXCR4
SCHEMBL4277843 0.80 ACHE (0.55) MEN1KMT2ACACNA1BHTR2ASIGMAR1
SCHEMBL3485073 0.80 CACNA1B (0.70) CACNA1BSIGMAR1NR1I2
SCHEMBL4277944 0.80 NPC1 (0.60) MEN1KMT2ALMNA
SCHEMBL13541677 0.79 CACNA1B (0.53) CACNA1BHTR2AHTR2CDRD2HTR7
SCHEMBL1682329 0.79 CXCR4 (0.48) MEN1KMT2AHTR2AKCNH2HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000174-B2 4-phenylsulfonamidopiperidines as calcium channel blockers PURDUE PHARMA L.P. (US) 2015-04-07 US disclosed
EP-1814851-B1 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO CELTIQUE SA (LU) 2013-06-05 EP disclosed
US-20090105249-A1 4-phenylsulfonamidopiperidines as calcium channel blockers EURO-CELTIQUE S.A. (LU) 2009-04-23 US disclosed
CN-101044116-A 4-phenylsulfonamidopiperidines as calcium channel blockers EURO CELTIQUE SA (LU) 2007-09-26 CN disclosed
EP-1814851-A2 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2007-08-08 EP disclosed
WO-2006040181-A2 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS EURO-CELTIQUE S.A. (LU) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105249-A1 4-phenylsulfonamidopiperidines as calcium channel blockers CACNA1A, CACNA1E, CACNA1B MEN1 3122/4885KMT2A 3553/4885CACNA1B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.